Although antibodies, at the time of writing, still dominate the clinic, there is a definite shift in the drug development pipeline towards more “complex”, next-generation molecules. These next-generation biologics (NGBs) include bispecifics and other novel format mAbs, novel glycoproteins and other complex molecules. They often combine domains from various molecules with engineered elements to create something that may not have been seen before in nature, with the result that they do not express well in current expression platforms. Alison Porter at Lonza analyses why the potential need for a different expression platform needs to be considered.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2019/11/Becoming-a-Champion-Go-Player.pdf” width=”100%” height=”900px” style=”border:0;”]